GammaGard Liquid, Immune Globulin Intravenous (Human)

Audience

Allergy and Immunology, Pediatrics

Issue

Baxter BioScience and FDA notified healthcare professionals of a market withdrawal being conducted as a precautionary measure due to an increased number of adverse event reports of allergic reactions associated with two lots of the product.

Background

GammaGard Liquid is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity.

Recommendation

Customers are asked to contact Baxter BioScience for Urgent Market Withdrawal instructions. See the Market Withdrawal Notice for information on affected lots.

Read the complete MedWatch 2010 Safety summary, including a link to the Market Withdrawal Notice

Tags: